Role of RT-PCR and FISH in diagnosis and monitoring of acute promyelocytic leukemia

Indian J Cancer. 2011 Jan-Mar;48(1):60-7. doi: 10.4103/0019-509X.75831.

Abstract

Background: Patients with a presence of Promyelocytic Leukemia-Retinoic Acid Receptor Alpha (PML-RARA) genes rearrangement predict a favorable response to all-trans retinoic acid (ATRA), and a significant improvement in survival. Therefore, establishing the presence of PML-RARA rearrangement is important for optimal patient management.

Aim: The objective of this study is to compare and assess the role of fluorescent in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR) in the diagnosis and long-term monitoring of Acute Promyelocytic Leukemia (APL).

Materials and methods: We compared 145 samples received at different interval of times to analyze the sensitivity of RT-PCR and FISH.

Results: The failure rate for RT-PCR was 4% at baseline, 13% at induction, and 0% at the end of consolidation. And for FISH it was 8% at baseline, 38% at induction, and 66% at the end of consolidation. The predictive values of relapse in the patients who were positive and negative by RT-PCR, at the end of induction, were 60% and 3%, respectively, and at end of consolidation it was 67% and 4%, respectively. On the other hand the predictive values of relapse in patients who were positive and negative by FISH at end of induction were 57% and 6%, respectively; while at end of consolidation it was 14% who were negative by FISH.

Conclusion: Both RT-PCR and FISH are important for the diagnosis of APL cases, as both techniques complement each other in the absence or failure of any one of them. However, RT-PCR is more sensitive than FISH for the detection of minimal residual disease in the long-term monitoring of these patients. The present study shows that the predictive value of relapse is more associated with minimal residual disease (MRD) results by RT-PCR than that by FISH.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Follow-Up Studies
  • Humans
  • In Situ Hybridization, Fluorescence*
  • Leukemia, Promyelocytic, Acute / diagnosis*
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / genetics
  • Neoplasm, Residual / diagnosis*
  • Neoplasm, Residual / drug therapy*
  • Neoplasm, Residual / genetics
  • Prognosis
  • RNA, Messenger / genetics
  • Reverse Transcriptase Polymerase Chain Reaction*
  • Treatment Outcome
  • Tretinoin / therapeutic use

Substances

  • Antineoplastic Agents
  • RNA, Messenger
  • Tretinoin